{"prompt": "['Yes, there is a reasonable', 'There is evidence of exposure to Merk product. The temporal sequence of the AE onset relative to the administration of Merk product is', 'possibility of Merck product', 'reasonable. The AE is more likely explained by Merk product than by another cause.', 'relationship.', 'No, there is not a reasonable', 'Participant did not receive the Merk product OR temporal sequence of the AE onset relative to administration of Merk product is not reasonable', 'possibility of Merck product', 'OR the AE is more likely explained by another cause than the Merk product. (Also entered for a participant with overdose without an associated', 'relationship', 'AE.)', '64']['8.0 STATISTICAL ANALYSIS PLAN', '8.1 Statistical Analysis Plan Summary', 'The primary outcome is objective response rate (complete and partial responses) at week 12', \"after the administration of lenvatinib and pembrolizumab. The Simon's two-stage design will\", 'be adopted for a possible early termination for futility. The null hypothesis that the true', 'response is 5% will be tested against a one-sided alternative. In the first stage, 9 patients will', 'be accrued, and if there is no responses among them, the study will be stopped for futility.', 'Otherwise, additional 8 patients will be accrued for a total of 17 patients (This does not', 'include screen failures and in-evaluable patients). The null hypothesis will be rejected if there', 'are 3 or more responses in 17 patients. The design yields a type I error rate of 0.05 and power', 'of 80% when the true response rate is 25%. The final response rate will be estimated with', '95% confidence interval by binomial test. The power calculation was from web-base', 'calculation developed by UNC Lineberger Comprehensive Cancer Center [36].', 'For the secondary objectives, the safety profile of the treatment will be documented and', 'summarized by summary statistics as frequency and percentage for each AE. Disease free', 'survival (DFS), which was defined as the interval between time of surgery and the first tumor', 'recurrence, or death. For overall survival, death from any cause will be defined as the event.', 'Patients will be censored at time of last follow-up. OS and DFS will be estimated with the', 'Kaplan-Meier method. The DFS and OS of each patient group at specific time points such as', '6 months, 1 year, 3 years, etc. and will be also estimated alone with 95% CI.', 'For the exploratory endpoint, paired t-test or Wilcoxon singed-rank test will be used to', 'compare the biomarkers change before, during, and after treatment. Summary statistics will', 'be applied to all items in the measurements for quality of life, frailty, and degree of', 'sarcopenia.', '9.0 LABELING, PACKAGING, STORAGE AND RETURN OF CLINICAL', 'SUPPLIES', '9.1', 'Investigational Product', 'The investigator shall take responsibility for and shall take all steps to maintain appropriate', 'records and ensure appropriate supply, storage, handling, distribution and usage of', 'investigational product in accordance with the protocol and any applicable laws and', 'regulations.', 'Pembrolizumab and lenvatinib will be provided by Merk as summarized in Table 11.', 'Table 11. Product Descriptions', '65']['Product Name & Potency', 'Dosage Form', 'Pembrolizumab 100 mg/4mL', 'Solution for Injection', 'Lenvatinib 10 mg and 4 mg', 'Capsule', '9.2 Packaging and Labeling Information', 'Supplies will be labeled in accordance with regulatory requirements.', '9.3 Clinical Supplies Disclosure', 'This trial is open-label; therefore, the participant, the trial site personnel, the Sponsor and/or', 'designee are not blinded to treatment. Drug identity (name, strength) is included in the label', 'text; random code/disclosure envelopes or lists are not provided.', '9.4', 'Storage and Handling Requirements', 'Clinical supplies must be stored in a secure, limited-access location under the storage', 'conditions specified on the label.', 'Receipt and dispensing of trial medication must be recorded by an authorized person at the', 'trial site.', 'Clinical supplies may not be used for any purpose other than that stated in the protocol.', '9.5 Returns and Reconciliation', 'The investigator is responsible for keeping accurate records of the clinical supplies received', 'from Merk or designee, the amount dispensed to and returned by the participants and the', 'amount remaining at the conclusion of the trial.', 'Upon completion or termination of the study, all unused and/or partially used', 'investigational product will be destroyed at the site per institutional policy. It is the', \"Investigator's responsibility to arrange for disposal of all empty containers, provided that\", 'procedures for proper disposal have been established according to applicable federal, state,', 'local and institutional guidelines and procedures, and provided that appropriate records of', 'disposal are kept.', '10.0 ADMINISTRATIVE AND REGULATORY DETAILS', '10.1 Data Reporting', 'Study staff are responsible for submitting data and/or data forms in the clinical management', 'system - Online Collaborative Research Environment (ONCORE) - per Winship SOP 4.2', 'Data Completion Metrics. Data completion will be reviewed monthly. In situations where', 'there are significant delays of data completion, the Associate Director of Clinical Research or', 'the Director of Clinical Trials may temporarily suspend enrollment. Data entry is to be', 'completed within the designated timeframe, not to exceed 30 days of the subject visit.', '66']\n\n###\n\n", "completion": "END"}